GGrantIndex
← Leaderboards

David Seth Goldberg

University Of Pennsylvania

Google Scholar ↗PubMed ↗ORCID ↗
$7,222,905
Attributed
$14,827,750
Total exposure
9
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.5M · FY2010–25
$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$17,514,445 · 10

By mechanism

U01$9,803,307 · 2
R01$6,440,515 · 5
K08$786,373 · 1
U34$362,250 · 1
F32$122,000 · 1

Top collaborators

Most similar at University Of Pennsylvania

Same institution · by research overlap

Others in their field

Top investigators on “Cohort”

Research focus

CohortTransplantationLiver DiseasesCessation Of LifeLiver TransplantationOrganWaiting ListsLiverFutureLifeResourcesPatient PopulationCaringTransplant RecipientsMortalityComorbidityUnited Network For Organ SharingProviderCirrhosisEvaluationPoliciesDeteriorationResearch PersonnelOrgan Donor

Grant awards (33)

A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT)$1,469,793
U01 · FY2025 · DK
The role of immunosuppression and environmental exposures on incident and subsequent keratinocyte carcinoma risk after solid organ transplant$441,578
R01 · FY2025 · CA
3/4-The INTEGRATE Study: Evaluating INTEGRATEd Care to Improve Biopsychosocial Outcomes of Early Liver Transplantation for Alcohol-Associated Liver Disease$399,892
R01 · FY2025 · AA · contact PI
Evaluating risk factors for cirrhosis progression and response to statin therapy among a cohort of patients with cirrhosis$388,501
U01 · FY2025 · DK · contact PI
A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT)$1,514,838
U01 · FY2024 · DK
Evaluating the impact of genetic ancestry and HIV on cirrhosis progression and response to statin therapy among a diverse multi-ethnic cohort of patients with cirrhosis$430,380
U01 · FY2024 · DK · contact PI
3/4-The INTEGRATE Study: Evaluating INTEGRATEd Care to Improve Biopsychosocial Outcomes of Early Liver Transplantation for Alcohol-Associated Liver Disease$399,037
R01 · FY2024 · AA · contact PI
A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT)$1,613,436
U01 · FY2023 · DK
Developing High-Quality Tools to Characterize Allograft Quality, Predict Transplant Outcomes and Expand Access to Kidney and Liver Transplantation$506,377
R01 · FY2023 · DK
Evaluating the impact of genetic ancestry and HIV on cirrhosis progression and response to statin therapy among a diverse multi-ethnic cohort of patients with cirrhosis$480,289
U01 · FY2023 · DK · contact PI
Using ethics, epidemiology and high-quality data to optimize the allocation of livers for transplantation$476,766
R01 · FY2023 · DK · contact PI
3/4-The INTEGRATE Study: Evaluating INTEGRATEd Care to Improve Biopsychosocial Outcomes of Early Liver Transplantation for Alcohol-Associated Liver Disease$386,427
R01 · FY2023 · AA · contact PI
A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT)$1,493,330
U01 · FY2022 · DK
Developing High-Quality Tools to Characterize Allograft Quality, Predict Transplant Outcomes and Expand Access to Kidney and Liver Transplantation$546,219
R01 · FY2022 · DK
Using ethics, epidemiology and high-quality data to optimize the allocation of livers for transplantation$512,808
R01 · FY2022 · DK · contact PI
Evaluating the impact of genetic ancestry and HIV on cirrhosis progression and response to statin therapy among a diverse multi-ethnic cohort of patients with cirrhosis$425,398
U01 · FY2022 · DK · contact PI
A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT)$1,676,144
U01 · FY2021 · DK
Using ethics, epidemiology and high-quality data to optimize the allocation of livers for transplantation$508,559
R01 · FY2021 · DK · contact PI
Developing High-Quality Tools to Characterize Allograft Quality, Predict Transplant Outcomes and Expand Access to Kidney and Liver Transplantation$479,002
R01 · FY2021 · DK
Evaluating the impact of genetic ancestry and HIV on cirrhosis progression and response to statin therapy among a diverse multi-ethnic cohort of patients with cirrhosis$311,198
U01 · FY2021 · DK · contact PI
Using ethics, epidemiology and high-quality data to optimize the allocation of livers for transplantation$539,884
R01 · FY2020 · DK · contact PI
Developing High-Quality Tools to Characterize Allograft Quality, Predict Transplant Outcomes and Expand Access to Kidney and Liver Transplantation$525,678
R01 · FY2020 · DK
Using ethics, epidemiology and high-quality data to optimize the allocation of livers for transplantation$555,285
R01 · FY2019 · DK · contact PI
A trial of transplanting Hepatitis C kidneys into Hepatitis C-Negative kidney recipients$362,250
U34 · FY2019 · DK
Using ethics, epidemiology and high-quality data to optimize the allocation of livers for transplantation$93,393
R01 · FY2019 · DK · contact PI
ConProject-001$69,610
R01 · FY2019 · DK · contact PI
A population-based cohort to study outcomes in end-stage liver disease patients$167,896
K08 · FY2017 · DK · contact PI
A population-based cohort to study outcomes in end-stage liver disease patients$154,119
K08 · FY2016 · DK · contact PI
A population-based cohort to study outcomes in end-stage liver disease patients$154,459
K08 · FY2015 · DK · contact PI
A population-based cohort to study outcomes in end-stage liver disease patients$154,789
K08 · FY2014 · DK · contact PI
A population-based cohort to study outcomes in end-stage liver disease patients$155,110
K08 · FY2013 · DK · contact PI
Access to Liver Transplantation for Patients with Primary Sclerosing Cholangitis$50,210
F32 · FY2011 · DK · contact PI
Access to Liver Transplantation for Patients with Primary Sclerosing Cholangitis$71,790
F32 · FY2010 · DK · contact PI